CellFE, Inc., a San Carlos, CA-based startup developing a microfluidics based device to deliver gene-editing molecules, completed a $4.8m seed round of financing.
The round was co-led by Dynamk Capital and Cota Capital with participation from Embark Ventures, Elm Ventures and McEwan Lane Family Trust. Dr. Gustavo Mahler, Venture Partner, Dynamk Capital and Cota Capital’s Founder and Managing Partner Bobby Yazdani will be joining the board of directors.
The company intends to use the funds to accelerate development of its solution to enable the engineering of the next generation cell therapies.
Led by Alla Zamarayeva, CEO, CellFE focuses on the application of microfluidics in the process of delivering gene-editing molecules into human cells. The company’s technology uses rapid cell compressions that drive cells to uptake molecules from the surrounding fluid.